Is The Allergen Really Needed in Allergy Immunotherapy?

Current Treatment Options in Allergy

Volumn 2, Issue 1, 2015, Pages 72-82

  Kündig, Thomas M ^a   Klimek, Ludger ^b   Schendzielorz, Philipp ^b   Renner, Wolfgang A ^c   Senti, Gabriela ^a   Bachmann, Martin F ^a,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Zentrum fur Rhinologie und Allergologie   (Germany)

^c AREBA Biotech AG   (Switzerland)

^d HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

Allergic rhinitis; Allergy; CpG motifs; Immunotherapy; Vaccine; Virus like particles

Indexed keywords

EID: 84947905445     PISSN: None     EISSN: 21963053     Source Type: Journal    
DOI: 10.1007/s40521-014-0038-5     Document Type: Review

References (82)

1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24:758–64. DOI: 10.1183/09031936.04.00013904
2. Bousquet J et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86:8–160. DOI: 10.1111/j.1398-9995.2007.01620.x
3. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102:558–62. DOI: 10.1016/S0091-6749(98)70271-4
4. Calderon, M.A., et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev CD001936 (2007).
5. Wise SK, Schlosser RJ. Subcutaneous and sublingual immunotherapy for allergic rhinitis: what is the evidence? Am J Rhinol Allergy. 2012;26:18–22. DOI: 10.2500/ajra.2012.26.3691
6. Cox L et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127:S1–S55. DOI: 10.1016/j.jaci.2010.09.034
7. Cox LS et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;117:1021–35. DOI: 10.1016/j.jaci.2006.02.040
8. Kariyawasam HK, Rotiroti G, Robinson DS. Sublingual immunotherapy in allergic rhinitis: indications, efficacy and safety. Rhinology. 2013;51:9–17.
9. Durham SR et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341:468–75. DOI: 10.1056/NEJM199908123410702
10. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy. 2002;57:306–12. DOI: 10.1034/j.1398-9995.2002.1o3264.x
11. Jacobsen L et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62:943–8. DOI: 10.1111/j.1398-9995.2007.01451.x
12. Moller C et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109:251–6. DOI: 10.1067/mai.2002.121317
13. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy. 2001;31:1392–7. DOI: 10.1046/j.1365-2222.2001.01161.x
14. Donahue JG, Greineder DK, Connor-Lacke L, Canning CF, Platt R. Utilization and cost of immunotherapy for allergic asthma and rhinitis. Annals Allergy Asthma Immunol. 1999;82:339–47. DOI: 10.1016/S1081-1206(10)63282-6
15. Hankin CS et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. J Allergy Clin Immunol. 2008;121:227–32. DOI: 10.1016/j.jaci.2007.10.026
16. Szeinbach SL, Williams PB, Kucukarslan S, Elhefni H. Influence of patient care provider on patient health outcomes in allergic rhinitis. Ann Allergy Asthma Immunol. 2005;95:167–74. DOI: 10.1016/S1081-1206(10)61207-0
17. Winther L, Arnved J, Malling HJ, Nolte H, Mosbech H. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study. Clin Exp Allergy. 2006;36:254–60. DOI: 10.1111/j.1365-2222.2006.02340.x
18. Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol. 2007;119:826–30. DOI: 10.1016/j.jaci.2007.01.025
19. Larche M. Update on the current status of peptide immunotherapy. J Allergy Clin Immunol. 2007;119:906–9. DOI: 10.1016/j.jaci.2007.02.015
20. Worm M, Patel D, Creticos PS. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis. Expert Opin Investig Drugs. 2013;22:1347–57. DOI: 10.1517/13543784.2013.827661
21. Patel D et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131(103–109):e101–7. This clinical trial demonstrates that allergen-derived oligopeptides representing CD4 T cell epitopes are sufficient for allergen-specific immunotherapy. These peptides do not bind IgE and therefore no longer cause allergic adverse events.
22. Senti G et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008;105:17908–12. This study demonstrates that allergen-specific immunotherapy can be shortened to only three injections if the allergen is delivered to the immune system more efficiently, i.e., by direct injection into a lymph node. DOI: 10.1073/pnas.0803725105
23. Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy: from the rationale to human applications. Curr Top Microbiol Immunol. 2011;352:71–84.
24. Kundig TM, Johansen P, Bachmann MF, Cardell LO, Senti G. Intralymphatic immunotherapy: time interval between injections is essential. J Allergy Clin Immunol. 2014;133:930–1. DOI: 10.1016/j.jaci.2013.11.036
25. Senti G et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129:1290–6. DOI: 10.1016/j.jaci.2012.02.026
26. Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol. 2013;131:412–20. DOI: 10.1016/j.jaci.2012.10.056
27. Mondoulet L et al. Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS One. 2012;7:e31967. DOI: 10.1371/journal.pone.0031967
28. Mondoulet L et al. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy. 2010;40:659–67. DOI: 10.1111/j.1365-2222.2009.03430.x
29. Mondoulet L et al. Epicutaneous immunotherapy compared with sublingual immunotherapy in mice sensitized to pollen (Phleum pratense). ISRN Allergy. 2012;2012:375735. DOI: 10.5402/2012/375735
30. Mondoulet L et al. Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice. Clin Transl Allergy. 2012;2:22. DOI: 10.1186/2045-7022-2-22
31. Mondoulet L et al. Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int Arch Allergy Immunol. 2010;154:299–309. DOI: 10.1159/000321822
32. Senti G, Freiburghaus AU, Kundig TM. Epicutaneous/transcutaneous allergen-specific immunotherapy: rationale and clinical trials. Curr Opin Allergy Clin Immunol. 2010;10:582–6. DOI: 10.1097/ACI.0b013e32833f1419
33. Senti G, von Moos S, Kundig TM. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy. 2011;66:798–809. DOI: 10.1111/j.1398-9995.2011.02560.x
34. von Moos S et al. The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy. Allergy. 2012;67:638–46. DOI: 10.1111/j.1398-9995.2012.02802.x
35. Senti G et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;124:997–1002. This is the first double-blind, placebo-controlled trial demonstrating that epicutaneous application of allergen extract can ameliorate allergy symptoms. DOI: 10.1016/j.jaci.2009.07.019
36. Senti G et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol. 2012;129:128–35. DOI: 10.1016/j.jaci.2011.08.036
37. Rosewich M, Lee D, Zielen S. Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis. Hum Vaccines Immunotherapeutics. 2013;9:1523–31. Recent review of the clinical data on MPLA used as an adjuvant in allergen-specific immunotherapy. DOI: 10.4161/hv.24631
38. Creticos PS et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med. 2006;355:1445–55. This clinical trial demonstrates that an allergen coupled to CpG represents an interesting therapeutic strategy in allergen-specific immunotherapy. DOI: 10.1056/NEJMoa052916
39. Kundig TM et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol. 2006;117:1470–6. First demonstration that allergens coupled to VLPs are highly immunogenic in humans. DOI: 10.1016/j.jaci.2006.01.040
40. Bachmann MF, Jennings GT. Therapeutic vaccines for chronic diseases: successes and technical challenges. Phil Trans R Soc B Biol Sci. 2011;366:2815–22. DOI: 10.1098/rstb.2011.0103
41. Klimek L, Schendzielorz P, Mueller P, Saudan P, Willers J. Immunotherapy of allergic rhinitis: new therapeutic opportunities with virus-like particles filled with CpG motifs. Am J Rhinol Allergy. 2013;27:206–12. DOI: 10.2500/ajra.2013.27.3875
42. Klimek L et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy. 2011;41:1305–12. This is the first study challenging the dogma that AIT requires the allergen. DOI: 10.1111/j.1365-2222.2011.03783.x
43. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10:787–96. DOI: 10.1038/nri2868
44. Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem. 2008;389:521–36. DOI: 10.1515/BC.2008.064
45. Garland SM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–43. Landmark study demonstrating that human papilloma virus infection and induction of cancer can be prevented by a VLP-based vaccine. DOI: 10.1056/NEJMoa061760
46. Paavonen J et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–70. Landmark study demonstrating that human papilloma virus infection and induction of cancer can be prevented by a VLP-based vaccine. DOI: 10.1016/S0140-6736(07)60946-5
47. Jennings GT, Bachmann MF. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol. 2009;49:303–26. DOI: 10.1146/annurev-pharmtox-061008-103129
48. Speiser DE et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother. 2010;33:848–58. DOI: 10.1097/CJI.0b013e3181f1d614
49. Braun M et al. Virus-like particles induce robust human T-helper cell responses. Eur J Immunol. 2012;42:330–40. DOI: 10.1002/eji.201142064
50. Goldinger SM et al. Nano-particle vaccination combined with TLR-7 and −9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients. Eur J Immunol. 2012;42:3049–61. DOI: 10.1002/eji.201142361
51. Cooper CL et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine. 2004;22:3136–43. DOI: 10.1016/j.vaccine.2004.01.058
52. Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev. 2001;50:3–20. DOI: 10.1016/S0169-409X(01)00150-8
53. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release. 2006;112:26–34. DOI: 10.1016/j.jconrel.2006.01.006
54. Manolova V et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008;38:1404–13. DOI: 10.1002/eji.200737984
55. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers—liposomes and microspheres—on the phagocytosis by macrophages. J Control Release. 2002;79:29–40. DOI: 10.1016/S0168-3659(01)00549-1
56. Yewdell JW. Designing CD8+ T cell vaccines: it’s not rocket science (yet). Curr Opin Immunol. 2010;22:402–10. DOI: 10.1016/j.coi.2010.04.002
57. Tewalt EF et al. Viral sequestration of antigen subverts cross presentation to CD8(+) T cells. PLoS Pathog. 2009;5:e1000457. DOI: 10.1371/journal.ppat.1000457
58. Steinman RM et al. The innate functions of dendritic cells in peripheral lymphoid tissues. Adv Exp Med Biol. 2005;560:83–97. DOI: 10.1007/0-387-24180-9_12
59. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004;5:1219–26. DOI: 10.1038/ni1141
60. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med. 2005;11:S63–8. DOI: 10.1038/nm1210
61. Plotkin SA. Vaccines: past, present and future. Nat Med. 2005;11:S5–S11. DOI: 10.1038/nm1209
62. Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Revi Vaccines. 2011;10:499–511. DOI: 10.1586/erv.10.174
63. Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev. 2008;60:795–804. DOI: 10.1016/j.addr.2007.12.004
64. Jegerlehner A et al. TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol. 2007;178:2415–20. DOI: 10.4049/jimmunol.178.4.2415
65. Hou B et al. Selective utilization of toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity. 2011;34:375–84. DOI: 10.1016/j.immuni.2011.01.011
66. Agrawal S, Gupta S. TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. J Clin Immunol. 2011;31:89–98. DOI: 10.1007/s10875-010-9456-8
67. Huber JP, Ramos HJ, Gill MA, Farrar JD. Cutting edge: Type I IFN reverses human Th2 commitment and stability by suppressing GATA3. J Immunol. 2010;185:813–7. DOI: 10.4049/jimmunol.1000469
68. Fransson M et al. Expression of toll-like receptor 9 in nose, peripheral blood and bone marrow during symptomatic allergic rhinitis. Respir Res. 2007;8:17. DOI: 10.1186/1465-9921-8-17
69. Bachmann MF et al. The influence of antigen organization on B cell responsiveness. Science. 1993;262:1448–51. This study demonstrates that repetitive antigen structures can induce B cell responses without T cell help. This study explains how the immune system can respond to VLPs so rapidly and vigorously, and has laid the basis for this technology. It also explains how T cell tolerance can be broken. DOI: 10.1126/science.8248784
70. Dynavax. Dynavax Tolamba™ chamber study misses primary endpoint. (2008). http://investors.dynavax.com/secfiling.cfm?filingID=1181431-08-32926. Accessed 16 Nov 2014.
71. Senti G et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy. 2009;39:562–70. DOI: 10.1111/j.1365-2222.2008.03191.x
72. Hessel EM et al. Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J Exp Med. 2005;202:1563–73. DOI: 10.1084/jem.20050631
73. Jagannathan M et al. TLR cross-talk specifically regulates cytokine production by B cells from chronic inflammatory disease patients. J Immunol. 2009;183:7461–70. DOI: 10.4049/jimmunol.0901517
74. Matsushima H, Yamada N, Matsue H, Shimada S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol. 2004;173:531–41. DOI: 10.4049/jimmunol.173.1.531
75. Kline JN. Eat dirt: CpG DNA and immunomodulation of asthma. Proc Am Thorac Soc. 2007;4:283–8. Excellent review on how bacterial products such as CpG can modulate asthma. DOI: 10.1513/pats.200701-019AW
76. Mellor AL et al. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J Immunol. 2005;175:5601–5. DOI: 10.4049/jimmunol.175.9.5601
77. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299:1259–60. This study laid the ground for the hygiene hypothesis, explaining why allergies are increasing in the modern industrialized world. DOI: 10.1136/bmj.299.6710.1259
78. Ball TM et al. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. N Engl J Med. 2000;343:538–43. DOI: 10.1056/NEJM200008243430803
79. Braun-Fahrlander C et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med. 2002;347:869–77. DOI: 10.1056/NEJMoa020057
80. Riedler J et al. Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet. 2001;358:1129–33. DOI: 10.1016/S0140-6736(01)06252-3
81. Begin P, Nadeau KC. Epigenetic regulation of asthma and allergic disease. Allergy Asthma, Clin Immuno. 2014;10:27. DOI: 10.1186/1710-1492-10-27
82. Ito T et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med. 2007;204:105–15. DOI: 10.1084/jem.20061660